(Q49141439)

English

Phase II study of prolonged oral therapy with etoposide (VP16) for patients with recurrent malignant glioma.

scientific article published in February 1996

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

18 February 2018

http://europepmc.org/abstract/MED/8699237

Phase II study of prolonged oral therapy with etoposide (VP16) for patients with recurrent malignant glioma. (English)

1 reference

Europe PubMed Central

18 February 2018

http://europepmc.org/abstract/MED/8699237

1 reference

based on heuristic

inferred from title

author name string

D Fulton

1

1 reference

Europe PubMed Central

18 February 2018

http://europepmc.org/abstract/MED/8699237

R Urtasun

2

1 reference

Europe PubMed Central

18 February 2018

http://europepmc.org/abstract/MED/8699237

P Forsyth

3

1 reference

Europe PubMed Central

18 February 2018

http://europepmc.org/abstract/MED/8699237

publication date

1 February 1996

1 reference

Europe PubMed Central

18 February 2018

http://europepmc.org/abstract/MED/8699237

Journal of Neuro-Oncology

1 reference

Europe PubMed Central

18 February 2018

http://europepmc.org/abstract/MED/8699237

27

1 reference

Europe PubMed Central

18 February 2018

http://europepmc.org/abstract/MED/8699237

2

1 reference

Europe PubMed Central

18 February 2018

http://europepmc.org/abstract/MED/8699237

149-155

1 reference

Europe PubMed Central

18 February 2018

http://europepmc.org/abstract/MED/8699237

https://scigraph.springernature.com/pub.10.1007/bf00177478

0 references

Etoposide (VP-16-213) in malignant brain tumors: a phase II study.

1 reference

https://pubmed.ncbi.nlm.nih.gov/8699237

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Proceedings: 4'-Demethyl-epipodophyllotoxin-beta-D-thenylidene-glucoside (PTG) in the treatment of malignant intracranial neoplasms

1 reference

https://pubmed.ncbi.nlm.nih.gov/8699237

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Etoposide. Current and future status

1 reference

https://pubmed.ncbi.nlm.nih.gov/8699237

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Intracarotid VP-16 in malignant brain tumors.

1 reference

https://pubmed.ncbi.nlm.nih.gov/8699237

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

VM 26 and VP 16-213: a comparative analysis

1 reference

https://pubmed.ncbi.nlm.nih.gov/8699237

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cell kinetic analyses of human malignant brain tumors (gliomas)

1 reference

https://pubmed.ncbi.nlm.nih.gov/8699237

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical and pharmacologic analysis of hyperfractionated daily oral etoposide

1 reference

https://pubmed.ncbi.nlm.nih.gov/8699237

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Penetration of VP-16 (etoposide) into human intracerebral and extracerebral tumors.

1 reference

https://pubmed.ncbi.nlm.nih.gov/8699237

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Chronic oral etoposide

1 reference

https://pubmed.ncbi.nlm.nih.gov/8699237

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cell proliferation patterns in the diagnosis of astrocytomas, anaplastic astrocytomas and glioblastoma multiforme: a Ki-67 study

1 reference

https://pubmed.ncbi.nlm.nih.gov/8699237

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Future directions for etoposide therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/8699237

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Therapeutic trials with VP-16-213 and VM-26: active agents in small cell lung cancer, non-Hodgkin's lymphomas, and other malignancies

1 reference

https://pubmed.ncbi.nlm.nih.gov/8699237

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Recurrent brainstem gliomas treated with oral VP-16.

1 reference

https://pubmed.ncbi.nlm.nih.gov/8699237

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

VM-26 as a second drug in the treatment of brain gliomas

1 reference

https://pubmed.ncbi.nlm.nih.gov/8699237

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

In situ analysis of cell kinetics in human brain tumors. A comparative immunocytochemical study of S phase cells by a new in vitro bromodeoxyuridine-labeling technique, and of proliferating pool cells by monoclonal antibody Ki-67.

1 reference

https://pubmed.ncbi.nlm.nih.gov/8699237

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Penetration of etoposide into human malignant brain tumors after intravenous and oral administration

1 reference

https://pubmed.ncbi.nlm.nih.gov/8699237

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

VM-26 monochemotherapy trial in the treatment of recurrent supratentorial gliomas: preliminary report.

1 reference

https://pubmed.ncbi.nlm.nih.gov/8699237

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/BF00177478

1 reference

Europe PubMed Central

18 February 2018

http://europepmc.org/abstract/MED/8699237

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

18 February 2018

http://europepmc.org/abstract/MED/8699237

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q49141439&oldid=1582954299"